NCT00602680View on ClinicalTrials.gov

Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

SSR180711C

duration of treatment: 4 weeks

DRUG

donepezil

duration of treatment: 4 weeks

DRUG

placebo

duration of treatment: 4 weeks

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Paris

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00602680 - Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter